Semi-Annual Consolidated Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7712868

Concept As at
2016-12-31
2016-01-01 to
2016-12-31
As at
2015-12-31
2015-01-01 to
2015-12-31
As at
2014-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-928,344,000 JPY
-854,701,000 JPY
Depreciation
15,364,000 JPY
16,764,000 JPY
Impairment losses
58,461,000 JPY
JPY
Interest and dividend income
-4,898,000 JPY
-3,591,000 JPY
Interest expenses
3,221,000 JPY
4,244,000 JPY
Foreign exchange losses (gains)
885,000 JPY
1,204,000 JPY
Decrease (increase) in trade receivables
-65,228,000 JPY
5,468,000 JPY
Decrease (increase) in inventories
592,000 JPY
3,070,000 JPY
Other, net
10,039,000 JPY
-10,002,000 JPY
Subtotal
-899,750,000 JPY
-752,324,000 JPY
Interest and dividends received
1,703,000 JPY
3,350,000 JPY
Interest paid
-3,261,000 JPY
-4,193,000 JPY
Income taxes paid
-2,115,000 JPY
-2,588,000 JPY
Net cash provided by (used in) operating activities
-903,424,000 JPY
-755,756,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-20,994,000 JPY
JPY
Proceeds from sale of property, plant and equipment
913,000 JPY
JPY
Purchase of investment securities
-112,620,000 JPY
-245,220,000 JPY
Net cash provided by (used in) investing activities
256,627,000 JPY
1,754,808,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-33,320,000 JPY
-33,320,000 JPY
Proceeds from issuance of shares
36,878,000 JPY
120,000 JPY
Net cash provided by (used in) financing activities
6,423,000 JPY
-120,060,000 JPY
Effect of exchange rate change on cash and cash equivalents
-885,000 JPY
-1,204,000 JPY
Net increase (decrease) in cash and cash equivalents
-641,259,000 JPY
877,786,000 JPY
Cash and cash equivalents
1,418,993,000 JPY
2,060,252,000 JPY
1,182,466,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.